Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts.

April 2017/in Publications /by awp-admin

Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, Balani DH, Ominsky MS, Ke HZ, Kronenberg HM, Wein MN
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts.
J Bone Miner Res. 2017;32(5):892-901 – PMCID: PMC5413385

News

Open Position: Tenure Track Position – Translational Research in Bone/Joint HealingAugust 2024 - 10:26 am
Click here for details and application JOB DESCRIPTION Wake Forest University School of Medicine invites applications to fill an open rank, tenure track position with an individual conducting translational research […]
CORT Pilot & Feasibility AwardJuly 2024 - 9:29 am
CORT Pilot & Feasibility Award Click here to download RFA The Center of Research Translation on Osteoporosis Bone Anabolic Therapies (CORT), based in the Endocrine Unit at MGH, and funded […]
Open Position: Research Lab Technician – Bastepe, Jueppner, Gardella labsJune 2024 - 3:40 pm
A Research Laboratory Technician I position is available in the laboratories of Drs. Murat Bastepe, Harald Jueppner, and Thomas Gardella in the Endocrine Unit at the Massachusetts General Hospital. This is […]
Opportunity: CSR Outstanding Manuscript AwardJune 2024 - 2:53 pm
CSR Outstanding Manuscript Award The Center for Musculoskeletal Research is delighted to announce an Outstanding Manuscript Award to be given to a First Author performing investigation in musculoskeletal research. […]

Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts.

Navigation

Contact us